Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BFRG
Upturn stock ratingUpturn stock rating

Bullfrog AI Holdings, Inc. Common Stock (BFRG)

Upturn stock ratingUpturn stock rating
$1.51
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: BFRG (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $

1 Year Target Price $

Analysts Price Target For last 52 week
$Target price
Low$
Current$1.51
high$

Analysis of Past Performance

Type Stock
Historic Profit -83.98%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.22M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.64
52 Weeks Range 1.23 - 4.84
Updated Date 06/29/2025
52 Weeks Range 1.23 - 4.84
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.8

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -78.05%
Return on Equity (TTM) -141.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 10607832
Price to Sales(TTM) 262.62
Enterprise Value 10607832
Price to Sales(TTM) 262.62
Enterprise Value to Revenue 205.12
Enterprise Value to EBITDA -12.02
Shares Outstanding 9415520
Shares Floating 7018332
Shares Outstanding 9415520
Shares Floating 7018332
Percent Insiders 25.96
Percent Institutions 4.5

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Bullfrog AI Holdings, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Bullfrog AI Holdings, Inc. focuses on developing and commercializing analytics solutions for complex diseases. Founded relatively recently, it aims to revolutionize drug development through its proprietary bfLEAPu2122 platform.

business area logo Core Business Areas

  • Drug Development Analytics: Provides predictive analytics to accelerate drug discovery and development, improve clinical trial outcomes, and enable precision medicine.
  • Defense Applications: Applies its analytics platform to defense and national security challenges, such as threat assessment and countermeasure development.
  • Government Applications: Provides data-driven insights for various government sectors.

leadership logo Leadership and Structure

Leadership details are available on their website but are not included here due to the evolving nature and access constraints. The company has a board of directors and a management team overseeing operations.

Top Products and Market Share

overview logo Key Offerings

  • bfLEAPu2122 Platform: A proprietary analytics platform that uses machine learning to identify patterns and predict outcomes in complex data sets. It finds patterns in highly dimensional data and allows users to predict outcomes. Market share data unavailable, key competitors includes BioSymetrics and GNS Healthcare. Precise revenue from this product is not publicly available.

Market Dynamics

industry overview logo Industry Overview

The healthcare analytics market is experiencing rapid growth, driven by the increasing availability of data, the need to improve drug development efficiency, and the growing adoption of precision medicine. This growth trend is also evident in other markets, such as defense, finance, and cybersecurity.

Positioning

Bullfrog AI aims to be a leader in predictive analytics for complex diseases, leveraging its unique bfLEAPu2122 platform. Competitive advantages are claimed in handling high-dimensional data and providing actionable insights. There is strong competition, but Bullfrog AI differentiates itself with its proprietary technology.

Total Addressable Market (TAM)

The total addressable market for AI in drug discovery is substantial, estimated to be in the billions of dollars. Bullfrog AI is positioned to capture a share of this market by providing analytics solutions that accelerate drug development and improve clinical trial outcomes.

Upturn SWOT Analysis

Strengths

  • Proprietary bfLEAPu2122 platform
  • Focus on complex diseases
  • Potential for disruptive innovation
  • Experience with defense & government applications

Weaknesses

  • Limited financial resources
  • Dependence on successful commercialization of bfLEAPu2122
  • Small market share
  • Lack of robust scientific backing

Opportunities

  • Partnerships with pharmaceutical companies
  • Expansion into new therapeutic areas
  • Increased adoption of AI in drug development
  • Government funding for AI-driven research

Threats

  • Competition from larger, established players
  • Regulatory hurdles in drug development
  • Rapid advancements in AI technology rendering bfLEAPu2122 obsolete
  • Economic downturn affecting research funding

Competitors and Market Share

competitor logo Key Competitors

  • GNS Healthcare (Privately Held)
  • BioSymetrics (Privately Held)
  • Recursion Pharmaceuticals, Inc. (RXRX)

Competitive Landscape

Bullfrog AI faces intense competition from larger companies with more established platforms and resources. Its competitive advantage lies in the bfLEAPu2122 platform and its focus on complex diseases. Its small size, however, limits its impact relative to larger competitors.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data is unavailable given the company's recent entry into the public market.

Future Projections: Future growth projections are dependent on successful commercialization of the bfLEAPu2122 platform and partnerships with pharmaceutical companies. Analyst estimates are limited due to the company's early stage.

Recent Initiatives: Recent initiatives include seeking partnerships with pharmaceutical companies and expanding its applications of the bfLEAPu2122 platform.

Summary

Bullfrog AI is a developing company that is looking to revolutionize drug development using its bfLEAPu2122 platform for complex diseases and its experience in the defense and government sectors. Limited resources and small market share create some problems in realizing this ambition, especially against bigger players in the field. Partnerships and further adoption of its product are key to long-term growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Third-party Market Research

Disclaimers:

This analysis is based on publicly available information and should not be considered financial advice. The information is current as of October 27, 2024, and may be subject to change. Market share estimates are approximations. Due to the rapidly changing nature of the market and data constraints, the accuracy of this analysis is limited. Financial performance should be independently verified.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bullfrog AI Holdings, Inc. Common Stock

Exchange NASDAQ
Headquaters Gaithersburg, MD, United States
IPO Launch date 2023-02-13
Founder, Chairman & CEO Mr. Vininder Singh
Sector Healthcare
Industry Health Information Services
Full time employees -
Full time employees -

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases; and Modified HSV-1, which is in the discovery phase, for the treatment of modified colorectal cancer. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It also has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.